Literature DB >> 21915609

Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.

Kuang-Hui Yu1, Yeong-Jian Jan Wu, Chang-Fu Kuo, Lai-Chu See, Yu-Ming Shen, Hsiao-Chun Chang, Shue-Fen Luo, Huei-Huang Ho, I-Jung Chen.   

Abstract

To estimate the mortality rate and identify factors predicting survival in patients with polymyositis (PM) and dermatomyositis (DM). The medical records of 192 PM/DM patients who were treated at Chang Gung Memorial Hospital from 1999 through 2008 were retrospectively reviewed. The Taiwan National Death Registry (1999-2008) was used to obtain their survival status. Thirty-one (16.1%) of the 192 patients with PM/DM had an associated malignancy; 41 (21.4%) had interstitial lung disease (ILD). During the follow-up period, 55 (28.6%) patients died and the overall cumulative survival rate was 79.3% at 1 year, 75.7% at 2 years, 69.9% at 5 years, and 66.2% at 10 years. In univariate analysis, older age at PM/DM onset, anemia, thrombocytopenia, leukopenia, diabetes mellitus, ILD, cancer, and non-use of azathioprine were associated with higher mortality (p = 0.0172, 0.0484, <0.0001, 0.0008, 0.0001, 0.0036, 0.0010, and 0.0019, respectively). In multivariate Cox regression analysis, thrombocytopenia (hazard ratio [HR] 4.94, 95% confidence interval [CI] 2.60-9.37, p < 0.0001), diabetes mellitus (HR 2.57, 95% CI 1.38-4.80, p < 0.0001), cancer (HR 2.30, 95% CI 1.26-4.22, p = 0.0030), and ILD (HR 1.98, 95% CI 1.11-3.51, p = 0.0182) were positively associated with mortality. Use of azathioprine (HR 0.35, 95% CI 0.16-0.74, p = 0.0064) was negatively associated with mortality. This study confirmed the high mortality rate (28.6%) in PM/DM patients. Survival time was significantly reduced in patients with thrombocytopenia, diabetes mellitus, ILD, and cancer patients than in those without these conditions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21915609     DOI: 10.1007/s10067-011-1840-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics.

Authors:  T H Lu; M C Lee; M C Chou
Journal:  Int J Epidemiol       Date:  2000-04       Impact factor: 7.196

Review 2.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

3.  Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis.

Authors:  I Marie; E Hachulla; P Y Hatron; M F Hellot; H Levesque; B Devulder; H Courtois
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

4.  Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.

Authors:  Y J Chen; C Y Wu; J L Shen
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

5.  Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy.

Authors:  P Ang; M W Sugeng; S H Chua
Journal:  Ann Acad Med Singap       Date:  2000-03       Impact factor: 2.473

6.  Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies.

Authors:  Pawel Mielnik; Ewa Wiesik-Szewczyk; Marzena Olesinska; Hanna Chwalinska-Sadowska; Jakub Zabek
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

7.  Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis.

Authors:  E H Kang; E B Lee; K C Shin; C H Im; D H Chung; S K Han; Y W Song
Journal:  Rheumatology (Oxford)       Date:  2005-06-21       Impact factor: 7.580

8.  Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases.

Authors:  J Benbassat; D Gefel; K Larholt; S Sukenik; V Morgenstern; A Zlotnick
Journal:  Arthritis Rheum       Date:  1985-03

9.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

10.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15
View more
  26 in total

Review 1.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

2.  Long-term follow-up of 62 patients with myositis.

Authors:  Janneke van de Vlekkert; Jessica E Hoogendijk; Marianne de Visser
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

Review 3.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

4.  Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.

Authors:  Chaminda Basnayake; Kathy Cash; Peter Blumbergs; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2013-12-13       Impact factor: 2.980

5.  Inflammatory myopathies: One-center experience.

Authors:  Metin Işık; Şule Bilgen; İsmail Doğan; Levent Kılıç
Journal:  Eur J Rheumatol       Date:  2014-09-01

6.  Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

Authors:  Justin M Oldham; Cathryn Lee; Eleanor Valenzi; Leah J Witt; Ayodeji Adegunsoye; Scully Hsu; Lena Chen; Steven Montner; Jonathan H Chung; Imre Noth; Rekha Vij; Mary E Strek
Journal:  Respir Med       Date:  2016-11-04       Impact factor: 3.415

Review 7.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

8.  Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort.

Authors:  Aswin M Nair; John Mathew; Ruchika Goel; Pramod Chebbi; Ashish Jacob Mathew; G Arvind; Bijesh Yadav; Grace Rebekah; John A J Prakash; Debashish Danda
Journal:  Clin Rheumatol       Date:  2021-01-27       Impact factor: 2.980

9.  Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.

Authors:  Surjit Singh; Deepti Suri; Roosy Aulakh; Anju Gupta; Amit Rawat; Rohit Manoj Kumar
Journal:  Clin Rheumatol       Date:  2014-07-23       Impact factor: 2.980

Review 10.  Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Authors:  Robert W Hallowell; Julie J Paik
Journal:  Clin Exp Rheumatol       Date:  2021-03-25       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.